Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Purified human pancreatic islets (PHPI) are a cellular therapy consisting of insulin-producing beta cells, along with alpha and delta cells, harvested from deceased donor pancreata. In the clinical research program led by Dr. Rodolfo Alejandro at the University of Miami's Diabetes Research Institute, these islets are transplanted into patients with type 1 diabetes mellitus, typically via infusion into the portal vein of the liver. The therapy is designed to restore endogenous insulin secretion and physiological glucose regulation, aiming to achieve insulin independence and prevent severe hypoglycemic episodes. This specific program often targets patients with type 1 diabetes who have already received a kidney transplant or those with impaired awareness of hypoglycemia and brittle diabetes.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on purified human pancreatic islets.